Notice NOT-AI-25-003 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-038 from the NIH Guide for Grants and Contracts

Notice NOT-HD-24-041 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-115 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement (i.e., applications can focus on a single condition). Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged. All applications must propose such studies in the context of a post-infectious etiology.

Funding Opportunity PAR-25-116 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications focused on the neurological and/or mental health-related manifestations of infection-associated chronic illnesses, including the post-acute sequelae of COVID-19 (Neuro-PASC) as well as other chronic illnesses with a potential infectious trigger (post-treatment Lyme Disease, myalgic encephalomyelitis/chronic fatigue syndrome [ME/CFS], postural orthostatic tachycardia syndrome [POTS], post-viral fatigue syndromes, etc.). Projects that investigate common neurological and/or mental health-related mechanisms across multiple infection-associated chronic illnesses would be of particular interest, although this is not a requirement (i.e., applications can focus on a single condition). Neurologically focused clinical research investigating scientifically compelling pathways that contribute to the development of infection-associated chronic illnesses - including basic experimental studies in humans (BESH) or mechanistic clinical trials that will accelerate the development of effective treatments - are within the scope of this initiative. Preclinical studies utilizing animal, cell culture, and/or human tissue models are also encouraged. All applications must propose such studies in the context of a post-infectious etiology.

Competitive: Sygnature Discovery Limited: About the role As a growing drug discovery organisation, we are looking for highly motivated, enthusiastic, talented individuals keen to carry out th Nottingham, United Kingdom

Notice NOT-OD-25-012 from the NIH Guide for Grants and Contracts

Notice NOT-NS-24-126 from the NIH Guide for Grants and Contracts

Notice NOT-NR-25-002 from the NIH Guide for Grants and Contracts

Notice NOT-NS-25-002 from the NIH Guide for Grants and Contracts

From £27,562 per annum: National Institute of Agricultural Botany (NIAB): Are you passionate about harnessing the power of molecular biology to tackle global agricultural challenges? Histon, Cambridge CB24 9NZ

Notice NOT-DA-24-050 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-071 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-25-072 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.

Funding Opportunity RFA-DA-25-070 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.

Notice NOT-OH-25-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-074 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this NOFO supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this NOFO supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientist.

Funding Opportunity PAR-25-075 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.

Funding Opportunity RFA-AI-24-068 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to stimulate the development of new treatments for genital herpes that suppress shedding and lesion formation and reduce transmission. This NOFO invites applications that propose research into a broad range of therapeutic approaches, including but not limited to development of new or improved antivirals, monoclonal antibodies, therapeutic vaccines, and gene editing technologies for treatment of patients living with genital herpes. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase is not guaranteed and will depend on the successful completion of milestones.

From £43,210 with benefits, subject to skills and experience: The Francis Crick Institute: The Developmental Signalling Laboratory headed by Caroline Hill focuses on cell signalling in early vertebrate development and disease London (Central), London (Greater)